High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1260-1268

  Pentheroudakis, George ^a   Goussia, Anna ^b   Voulgaris, Evangelos ^a   Nikolaidis, Konstantinos ^a   Ioannidou, Evaggelia ^b   Papoudou Bai, Alexandra ^b   Grepi, Konstantina ^b   Kanavaros, Panagiotis ^b   Pavlidis, Nicholas ^a   Bai, Maria ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

anthracyclines; B cell lymphomas; differentiation immunophenotype; prognosis; Topoisomerase II

Indexed keywords

CD103 ANTIGEN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) 2ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; KI 67 ANTIGEN; PREDNISONE; PROTEIN BCL 6; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; GENE AMPLIFICATION; GERMINAL CENTER; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISOLONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77954126670     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.483749     Document Type: Article

References (43)

1. Kaufmann WK. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 1998;217:327-334.
2. Liu LF. DNA topoisomerase poison as antitumour drugs. Ann Rev Biochem 1989;58:351-375.
3. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A:958-966.
4. Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002;20:570-589.
5. Bandele OJ, Osheroff N. The efficacy of topoisomerase IItargeted anticancer agents reflects the persistence of druginduced cleavable complexes in cells. Biochemistry 2008;47: 11900-11908.
6. Burgess DJ, Dole J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008;105:9053-9058.
7. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non- Hodgkin's lymphomas. Am J Clin Pathol 1995;104:54-59.
8. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-350.
9. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul 1993;33:113-127.
10. Tanner M, Isola J, Wiklund T, et al. topoisomerase IIA gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER2/neu amplified breast cancer. Results from the randomised trial SBG9401. J Clin Oncol 2006;24:2428-2438.
11. Olsen K, Knudsen H, Rasmussen B, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004;43:35-42.
12. Pileri SA, Dirnhofer S, Went P, et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002; 41:482-509.
13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
14. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003;103:275-282.
15. Bai M, Skyrlas A, Agnantis NJ, et al. Relationships between Bcell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res 2005;25:347-362.
16. Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B cell lymphomas. Mod Pathol 2003;16:471-480.
17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria formalignant lymphoma. J Clin Oncol 2007;25:579-586.
18. Tanne M, Jarvineu P, Isola J, et al. Amplification of HER-2/ neu and topoisomerase II-a in primary and metastatic breast cancer. Cancer Res 2001;61:5345-5348.
19. Bai M, Vlahonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B cell lymphomas. Mod Pathol 2001; 14:1105-1113.
20. Bai M, Tsanou E, Agnantis NJ, et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferative activity and apoptosis status in diffuse large B cell lymphomas. Histol Histopathol 2003;18:449-457.
21. Bai M, Tsanou E, Skyrlas A, Sainis I, Agnantis N, Kanavaros P. Alterations of the p53, Rb and p27 tumour suppressor pathways in diffuse large B-cell lymphomas. Anticancer Res 2007;27:2345-2352.
22. Scarlos DV, Bai M, Goussia A, et al. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res 2007;27:2973-2983.
23. Mass R, Press M, Anderson S, et al. Evaluation of clincal outcomes according to HER2 detection by FISH in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-246.
24. Bhargava R, Lai P, Chen B. HER2/neu and topoisomerase IIA gene amplification and protein expession in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123:889-895.
25. Gennari A, Sormani M, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomised trials. J Natl Cancer Inst 2008; 100:14-20.
26. O'Malley FP, Chai S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644-650.
27. Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12-q21 amplicon: HER2 and topoisomerase IIA and their importance to the biology of solid tumours. Cancer Treat Rev 2007;33:64-77.
28. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER2 gene status in gastric carcinoma using immunohistochemistry, FISH and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393.
29. Szvalb S, Stein M, Gershuny A, Gez E, Hadary A, Zidan J. Lack of HER2 gene amplification in non Hodgkin lymphoma using chromogenic in situ hybridisation test. Leuk Lymphoma 2009;50:736-740.
30. Provencio M, Corbacho C, Salas C, et al. The topoisomerase IIA expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003;9: 1406-1411.
31. Lohri A, Reuter J, Gudat F, Herrmann R. Topoisomerase IIA mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. J Clin Pathol 1997;50:22-26.
32. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. topoisomerase IIA expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008;14:1759-1766.
33. Korkolopoulou P, Angelopoulou M, Siakantari M, et al. Evaluation of DNA topoisomerase IIA expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology 2001;38:45-53.
34. Schrader C, Meusers P, Brittinger G, et al. Topoisomerase IIA expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004;18:1200-1206.
35. Wang YH, Takanashi M, Tsuji K, et al. Level of DNA topoisomerase IIA mRNA predicts the treatment response of relapsed acute leukemic patients. Leuk Res 2009;33:902-907.
36. Stammler G, Sauerbrey A, Volm M. Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR. Cancer Lett 1994;84:141-147. (Pubitemid 24280145)
37. Lodge AJ, Hall AG, Reid MM, et al. Topoisomerase IIA and IIB expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome. J Clin Pathol 2001;54:31-36.
38. Oiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM- 26-induced cytotoxicity. Biochemistry 1996;50:16354-16360.
39. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene-expression based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;19:9991-9996.
40. Davis RE, Brown KD, Siebenlist U, et al. Constitutive NFkB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874.
41. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med 2002;346:1937-1947.
42. Ohsima K, Kawasaki C, Muta H, et al. CD10 and BCL10 expression in DLBCL: CD10 is a marker of improved prognosis. Histopathology 2002;39:156-162.
43. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene BCL6 strongly predicts survival in patients with DLBCL. Blood 2001;98:945-951.